Literature DB >> 28839671

Fragility fracture risk in cirrhosis: a comparison of the fracture risk assessment tool, British Society of Gastroenterology and National Institute for Health and Clinical Excellence guidelines.

Lachlan Richard Owen Ayres1, Shane Clarke2, Jonathan Digby-Bell1, Ashwin Deep Dhanda1, Suranga Dharmasiri1, Katharine Caddick1, Peter Lesley Collins1.   

Abstract

OBJECTIVE: Low bone mineral density (BMD) is common in chronic liver disease and predisposes to fracture. We aimed to compare British Society of Gastroenterology (BSG) and National Institute for Health and Clinical Excellence (NICE) osteoporosis guidelines with the fracture risk assessment tool (FRAX). FRAX is a web-based algorithm used to estimate fracture risk with or without dual-emission x-ray absorptiometry (DXA). Pre-BMD FRAX categorises patients to low, intermediate or high risk according to thresholds set by the National Osteoporosis Guidelines Group (NOGG) and recommends lifestyle advice, DXA or anti-osteoporosis treatment, respectively.
DESIGN: The guidelines were applied to 132 patients with cirrhosis (91% Child-Pugh A). The number that would require DXA and be recommended treatment was determined. Using post-BMD FRAX/NOGG as a reference point, high-risk patients not recommended treatment and low-risk patients treated 'unnecessarily' were identified.
RESULTS: BSG guidelines were applicable to 100% of the cohort, 88% required DXA and 30% would be recommended treatment. Equivalent figures for NICE guidelines were 30%, 17% and 12%, and for FRAX/NOGG guidelines were 78%, 27% and 15%, respectively. Using BSG guidance 8% of high-risk patients were not recommended treatment and 62% of those treated were low risk, compared with NICE: 3%, 60% and FRAX/NOGG: 13%, 40%, respectively.
CONCLUSION: For patients with Child-Pugh A cirrhosis BSG guidelines are the most inclusive, but have high cost implications in terms of DXA scanning and unnecessary treatment. Risk stratification using FRAX requires fewer DXA scans with minimal impact in terms of missing high-risk patients, and yields a modest reduction in unnecessary treatment.

Entities:  

Keywords:  CIRRHOSIS

Year:  2012        PMID: 28839671      PMCID: PMC5369821          DOI: 10.1136/flgastro-2012-100186

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  14 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

3.  Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease.

Authors:  O M Crosbie; R Freaney; M J McKenna; J E Hegarty
Journal:  Calcif Tissue Int       Date:  1999-04       Impact factor: 4.333

4.  Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.

Authors:  A Monegal; M Navasa; N Guañabens; P Peris; F Pons; M J Martinez de Osaba; A Rimola; J Rodés; J Muñoz-Gómez
Journal:  Calcif Tissue Int       Date:  1997-02       Impact factor: 4.333

5.  Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.

Authors:  F J Gallego-Rojo; J L Gonzalez-Calvin; M Muñoz-Torres; J L Mundi; R Fernandez-Perez; D Rodrigo-Moreno
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis.

Authors:  N Guañabens; A Monegal; A Muxi; A Martinez-Ferrer; R Reyes; J Caballería; L Del Río; P Peris; F Pons; A Parés
Journal:  Osteoporos Int       Date:  2011-08-30       Impact factor: 4.507

7.  Bone mineral density among cirrhotic patients awaiting liver transplantation.

Authors:  Rana Paramvir Sokhi; Abhinandana Anantharaju; Ravi Kondaveeti; Steven D Creech; Khondker K Islam; David H Van Thiel
Journal:  Liver Transpl       Date:  2004-05       Impact factor: 5.799

8.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

9.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18

10.  Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Authors:  J A Kanis; E V McCloskey; H Johansson; O Strom; F Borgstrom; A Oden
Journal:  Osteoporos Int       Date:  2008-08-28       Impact factor: 4.507

View more
  1 in total

1.  Hepatic osteodystrophy and fracture risk prediction using FRAX tool in Indian patients with cirrhosis.

Authors:  Arka De; Debadrita Ray; Sandeep Lamoria; Vishal Sharma; Tilak Raj Khurana
Journal:  JGH Open       Date:  2020-06-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.